Medscape

Forest to Discontinue Memantine 5-, 10-mg Tablets

Forest Laboratories announced today that the company will discontinue sale of memantine (Namenda) 5-mg and 10-mg tablets effective August 15, 2014, in favor of focusing on sales of its once-daily ...
Nasdaq

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Medscape

Memantine: A Treatment for Alzheimer's Disease With a New Formulation

† Noted adverse events were experienced in ≥5% of either treatment group, and had an incidence more than or equal to twice as great in memantine-treated patients than in placebo-treated patients. AE: ...
FiercePharma

Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride

- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS ...
Healio

Memantine may help prevent cognitive decline after brain radiation

Please provide your email address to receive an email when new articles are posted on . Cognitive decline is one of the potential adverse effects of cranial radiation therapy in cancer patients. It ...
News Medical

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan plc (NYSE: AGN), today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement ...
FierceBiotech

Forest and Merz Announce FDA Approval of NAMENDA XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type

Forest and Merz Announce FDA Approval of NAMENDA XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type NEW YORK, Jun 21, 2010 (BUSINESS WIRE ...
Nature

The Effects of Memantine on Prepulse Inhibition

The methods used in this study were approved by the UCSD Human Subject Institutional Review Board (human studies) or were in accordance with the National Institute of Health Guide for the Care and Use ...
ascopubs.org

Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma.

Association of anticonvulsant prophylaxis in patients with primary and metastatic brain tumors and 1-year overall survival: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from ...
GEN

Actavis-Adamas Alzheimer’s Treatment Wins FDA Nod

Actavis and Adamas Pharmaceuticals said today they won FDA approval for Namzaric, in a rare favorable outcome for treatments indicated for Alzheimer’s disease. Namzaric is indicated for the treatment ...
FiercePharma

Actavis and Adamas Announce FDA Approval of NamzaricTM, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride

- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS ...